Nevertheless, when anti-PD-1 is added in this context, it leads to tumour eradication in some mice and development of immune memory, indicating that targeting both KRASG12C and SHP2 can sensitise non-immunogenic tumours to anti-PD-1 therapies and achieve long-term responses. Here, PDCD1 is linked to neoplasm.